In conclusion, given the importance of assessing the therapeutic window of antiresorptives during osteoporosis treatment as well as their inhibitory effects on bone resorption or their stimulatory effects on bone formation, this study investigated whether TRACP‐5b/BAP score might prove useful in determining the therapeutic window of each osteoporosis treatment and predicting BMD changes after treatment. This evidence concerns the gene ACP5 and osteoporosis.